Periodontal Disease and Circulatory Microbial Components
| Status: | Completed |
|---|---|
| Conditions: | Dental |
| Therapuetic Areas: | Dental / Maxillofacial Surgery |
| Healthy: | No |
| Age Range: | 35 - Any |
| Updated: | 5/5/2014 |
| Start Date: | January 2010 |
| End Date: | January 2011 |
| Contact: | Lea M Franco, MS, BS |
| Email: | mcohrclinicalresearch@umich.edu |
| Phone: | 734-998-6721 |
Circulatory Microbial Components and Immune Regulators of Patients With Periodontal Disease and Rheumatoid Arthritis
The goal of this project is to study the immune activity of certain proteins present in the
blood of patients with severe periodontal disease. Periodontal disease (gum disease) is the
major cause of tooth loss among adults. Moderate to severe periodontal disease is reported
to affect 5-15% of American adults. It begins with an infection of the tissues surrounding
the teeth, and leads to a worsening inflammatory response. This study will aid in clarifying
the way in which gum disease might affect certain systemic diseases, such as rheumatoid
arthritis.
blood of patients with severe periodontal disease. Periodontal disease (gum disease) is the
major cause of tooth loss among adults. Moderate to severe periodontal disease is reported
to affect 5-15% of American adults. It begins with an infection of the tissues surrounding
the teeth, and leads to a worsening inflammatory response. This study will aid in clarifying
the way in which gum disease might affect certain systemic diseases, such as rheumatoid
arthritis.
This project will have two specific goals: 1. Identify microorganism components in the serum
of patients with severe periodontitis; and 2. Characterize the immune regulator activity of
periodontitis serum. This proposed feasibility study will then aid in providing the support
for an increased sample size and other design requirements for larger, more expanded human
clinical trial testing.In this study, eighty (80) subjects will be divided into 4 groups: 1)
Healthy oral status group; 2) Severe periodontal disease; 3) Healthy oral status group WITH
RHEUMATOID ARTHRITIS; 4)Severe periodontal disease WITH RHEUMATOID ARTHRITIS. Patients will
be clinically screened using standard periodontal measurements.
of patients with severe periodontitis; and 2. Characterize the immune regulator activity of
periodontitis serum. This proposed feasibility study will then aid in providing the support
for an increased sample size and other design requirements for larger, more expanded human
clinical trial testing.In this study, eighty (80) subjects will be divided into 4 groups: 1)
Healthy oral status group; 2) Severe periodontal disease; 3) Healthy oral status group WITH
RHEUMATOID ARTHRITIS; 4)Severe periodontal disease WITH RHEUMATOID ARTHRITIS. Patients will
be clinically screened using standard periodontal measurements.
Inclusion Criteria:
- 35 years or older
- Healthy patients or patients with severe periodontal disease
- Patients with or without Rheumatoid Arthritis
- Patients with at least 20 permanent teeth
Exclusion Criteria:
- Patients undergoing long-term (over 2 weeks) antibiotic-related therapy 3 months
prior to study inclusion
- Patients receiving periodontal treatment 12 months prior to study inclusion
(INCLUDING CLEANINGS)
- Patients will be excluded if they receive long-term use of medications known to
affect periodontal status such as anti-inflammatory drugs, aspirin and ibuprofen
- Patients on immunosuppressive therapies, including glucocorticoids or cyclosporines,
are excluded from participation in this study (inhalers are allowed)
- History of metabolic bone diseases such as rheumatoid arthritis or post-menopausal
osteoporosis
- Pregnant women or women attempting to become pregnant
We found this trial at
1
site
Click here to add this to my saved trials
